Episode
Future Directions in Relapsed and Refractory Large B-cell Lymphoma
- Podcast
- Blood Podcast
- Published
- Jun 11, 2026
- Duration seconds
- 1518
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/de6fdfa2
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/future-directions-in-relapsed-and-refractory-large-b-cell-lymphoma.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “ From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma ”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.